Fairmount Funds Management LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802528

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth Tilt how tags are computed

Q2 2024 · 13 positions · Total reported value $885.12M · Top-10 concentration 94.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 15.4% · 1 new · 0 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +31.7% · vs SPY +16.9% · Prev Value $1.38B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2024 13F filing, Fairmount Funds Management LLC disclosed 13 equity positions with a combined reported value of $885.12M. The filing implies a focused portfolio: its ten largest positions account for 94.3% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt.

The largest disclosed positions as of Q2 2024 were AXSM ($189.99M), NUVL ($146.00M), SYRE ($94.47M). By sector, the heaviest allocations are Health Care 70.2%, Other 29.8%. Versus the prior quarter, allocation shifted toward Health Care (+11.2pp) and away from Other (-11.2pp).

Versus the prior quarter, Fairmount Funds Management LLC opened 1 new positions, trimmed 0 and fully exited 1, a turnover rate of 15.4% of positions. The portfolio's overlap with the prior quarter was 75% of names.

The largest new positions opened in Q2 2024 were BCYC ($21.64M).

Of the 1 positions fully exited versus the prior quarter, the largest were MRUS ($32.30M), TYRA ($22.85M), GERN ($22.00M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • BCYC BICYCLE THERAPEUTICS PLC · $21.64M

Fully Exited (vs previous quarter)

  • MRUS MERUS N V · prev qtr: $32.30M
  • TYRA TYRA BIOSCIENCES INCORPORATED · prev qtr: $22.85M
  • GERN GERON CORP COM · prev qtr: $22.00M

Insider Transactions (Form 4)

Latest Fairmount Funds Management LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-09-03 D Apogee Therapeutics, Inc. 51,166 — SEC filing
2026-09-03 D Apogee Therapeutics, Inc. 340,855 — SEC filing
2026-08-07 Opt exercise Apogee Therapeutics, Inc. 10,370 $43.85 SEC filing
2026-08-07 Opt exercise Apogee Therapeutics, Inc. 31,838 $17.00 SEC filing
2026-07-16 Buy CRESCENT BIOPHARMA, INC. 853,450 $14.50 SEC filing
2026-07-01 Sell Oruka Therapeutics, Inc. 3,553,410 $84.43 SEC filing
2026-07-01 Conversion Oruka Therapeutics, Inc. 3,553,410 — SEC filing
2026-06-23 Sell Spyre Therapeutics, Inc. 4,684,781 $85.31 SEC filing

All insider transactions →

Fund Profile

Fairmount Funds Management LLC, based in West Conshohocken, PA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 12 positions worth $1.51B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: WEST CONSHOHOCKEN, PA, United States
  • SEC registration: 801-116848 (status: Approved), registered 2019-06-27
  • Regulatory AUM (Form ADV): $5.80B as of 2026-08-07
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 6 private funds, of which 1 hedge funds
  • Website: fairmountfunds.com

Portfolio Structure

  • 12 positions · $1.51B reported value (Q2 2026)
  • Top 10 holdings = 97.6% of reported value
  • Largest position: ORKA (ORUKA THERAPEUTICS INC) at 23.3%
  • Average position size: $126.08M

Sector Tilt

  • Health Care 96.2%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 1 new, 1 added, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 70.2%
Other 29.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.36M $189.99M 21.46%
21.46%
Hold
2 1.92M $146.00M 16.50%
16.50%
Hold
3 4.02M $94.47M 10.67%
10.67%
Add
4 2.05M $80.61M 9.11%
9.11%
Hold
5 3.20M $74.85M 8.46%
8.46%
Hold
6 2.76M $71.50M 8.08%
8.08%
Hold
7 3.20M $59.83M 6.76%
6.76%
Hold
8 6.23M $52.48M 5.93%
5.93%
Add
9 3.55M $32.34M 3.65%
3.65%
Hold
10 931.89K $32.29M 3.65%
3.65%
Hold
11 1.85M $24.01M 2.71%
2.71%
Hold
12 1.07M $21.64M 2.44%
2.44%
New
13 749.00K $5.10M 0.58%
0.58%
Reduce

FAQ

What did Fairmount Funds Management LLC buy in 2024-Q2?

In its 2024-Q2 13F filing, Fairmount Funds Management LLC reported 13 equity positions worth $885.12M in aggregate; its largest disclosed positions were AXSM ($189.99M), NUVL ($146.00M), SYRE ($94.47M).

How large is Fairmount Funds Management LLC's portfolio?

Fairmount Funds Management LLC reported $885.12M of long equity holdings across 13 positions as of 2024-Q2. Top-10 holdings account for 94.3% of reported value.

What is Fairmount Funds Management LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/fairmount-funds-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →